Investigates lncRNA AP000654.1’s role in regulating NLRP3 inflammasome activation in microglia, suggesting therapeutic potential for ischemic stroke.
Background Ischemic stroke (IS) remains a leading cause of disability worldwide, and its therapeutic window is very narrow. Ischemia-reperfusion injury exacerbates secondary brain damage. Microglial NLRP3 inflammasome activation drives neuroinflammation, yet its upstream regulation requires further elucidation. We previously identified lncRNA AP000654.1 as significantly downregulated in the peripheral blood of stroke patients, prompting our investigation into its potential role in microglial biology. Methods Using an in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model in HMC3 human microglial cells, we investigated the role of lncRNA AP000654.1—previously identified as significantly downregulated in peripheral blood of stroke patients—in regulating microglial inflammatory responses. Results OGD/R treatment upregulated NLRP3 inflammasome-related genes, induced pyroptosis-associated changes, and altered mitophagy markers. LncRNA AP000654 0.1 overexpression suppressed this excessive mitophagy by inhibiting the PINK1-Parkin pathway, thereby improving mitochondrial function. This suppression subsequently attenuated NLRP3 inflammasome assembly and pyroptosis. Crucially, enforcing mitophagy with rapamycin exacerbated the injury, which was effectively rescued by lncRNA AP000654. Conclusion LncRNA AP000654.1 is associated with suppression of excessive mitophagy-assocated mitochondrial stress and NLRP3 inflammasome activation in microglia, suggesting its potential relevance as a therapeutic target in ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: